Epigenetic Reprogramming Drives Epithelial Disruption in Chronic Obstructive Pulmonary Disease

Area of Science:

• Pulmonary Medicine
• Epigenetics
• Cell Biology

Background:

• Chronic obstructive pulmonary disease (COPD) significantly impacts global health, with epithelial alterations being a known but poorly understood feature.
• Current therapeutic strategies for COPD do not specifically target epithelial dysfunction.

Purpose of the Study:

• To investigate the role of epigenetic reprogramming of E-cadherin (encoded by the CDH1 gene) in disrupting epithelial integrity in COPD.
• To explore whether targeting these epigenetic modifications can restore epithelial integrity and mitigate lung tissue destruction.

Main Methods:

• Utilized differentiated normal and COPD-derived human airway epithelial cells, genetically modified mouse tracheal epithelial cells, and human precision-cut lung slices.
• Assessed epigenetic modifications, DNA methylation, and RNA polymerase II binding at the CDH1 gene enhancer.
• Administered the DNA demethylation agent 5-aza-2'-deoxycytidine to COPD-derived lung tissue.

Main Results:

• Identified increased DNA methylation at the CDH1 enhancer D in COPD, linked to the downregulation of the TET1 enzyme.
• Demonstrated that this methylation reduces RNA polymerase II binding, contributing to CDH1 silencing and loss of epithelial integrity.
• Showed that 5-aza-2'-deoxycytidine treatment reduced cell damage and air space enlargement in COPD lung slices.

Conclusions:

• Loss of E-cadherin in COPD results from epigenetic silencing via DNA methylation, mediated by reduced TET1 activity.
• Epigenetic reprogramming targeting DNA demethylation represents a novel therapeutic strategy to reverse tissue remodeling in COPD.
• This study provides a proof of concept for developing disease-modifying treatments for COPD by targeting epigenetic mechanisms.